Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Intelligence

Set Alert for Market Intelligence

UK Price Movements Muted In A Quiet December

As the UK continued to see a mixture of national lockdown measures and regional restrictions to mitigate the coronavirus pandemic, as well as preparing for the end of its transition period with the EU and the end-of-year holiday period, price changes were unusually muted in December.

Market Intelligence Pricing Strategies

COVID-19 Alters But Doesn’t Change M&A Machine In 2020

Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.

M & A Deals

US Biosimilars See A Banner Year Despite Few Approvals

With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.

Biosimilars United States

UK Turbulence Not Expected To Disrupt Supply

Despite Brexit uncertainty and travel restrictions that have just been imposed on the UK, the country’s generics industry is not expected to suffer major disruptions.

Brexit Coronavirus COVID-19

Exemestane Prices Tumble As UK Sees Reductions

Exemestane 25mg tablets saw their average UK trade price drop by a third in November, according to the latest figures from WaveData.

Market Intelligence Pricing Strategies

Australian Confidence In Biosimilar Switching ‘More Than Doubled Since 2016’

A new reported commissioned by Australia’s Generic and Biosimilar Medicines Association shows a ‘marked increase’ in confidence for biosimilars among a number of different stakeholders.

Biosimilars Market Intelligence
See All